Grifols (NASDAQ:GRFS) Shares Gap Down – Here’s What Happened

Grifols, S.A. (NASDAQ:GRFS) shares gapped down before the market opened on Monday . The stock had previously closed at $9.47, but opened at $9.22. Grifols shares last traded at $9.20, with a volume of 295,168 shares.

Analysts Set New Price Targets

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Trading Down 8.2 %

The business has a 50-day simple moving average of $8.88 and a 200-day simple moving average of $8.04. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in shares of Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 1,135 shares in the last quarter. Signaturefd LLC increased its stake in Grifols by 66.2% in the third quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 2,153 shares during the last quarter. HighTower Advisors LLC raised its holdings in Grifols by 12.5% during the third quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 1,546 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Grifols during the 2nd quarter worth approximately $89,000. Finally, Chesapeake Capital Corp IL acquired a new position in shares of Grifols in the 3rd quarter valued at $148,000.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.